Objectives: The intensity of post-egg retrieval pain is underestimated, with few studies examining postprocedural pain and predictors to identify women at risk for severe pain. We evaluated the influence of preprocedural hormonal levels, ovarian factors, and mechanical temporal summation (mTS) as predictors for postegg retrieval pain in women undergoing in vitro fertilization.
I n the Unites States, >150,000 assisted reproductive technology (ART) procedures were performed in 2011, 1 with numbers anticipated to further increase. Oocyte retrieval is only 1 of many steps and painful procedures that women will experience before becoming a parent. Women undergoing ART report escalating pelvic discomfort in the later stages of ovulation induction and most women use potent analgesics after oocyte retrieval procedures. 2, 3 Because postprocedural pain has not been extensively studied and management is challenging due to concerns that anti-inflammatory drugs may interfere with the fertility process, women are at risk for being either undertreated or overtreated with prescribed opioids that may not necessarily be effective or even needed.
Discomfort and pain after ART has been attributed to the mechanical process of ovarian enlargement similar to midcycle pelvic pain (Mittleschmerz), 4 the operative procedure itself, and the resulting postoperative accumulation of peritoneal fluid and blood. 5 The ovulation induction protocols utilized in ART are designed to induce supraphysiological oocyte recruitment. With continued ovulation induction, follicular recruitment results in significant bilateral ovarian enlargement from multiple follicles and supraphysiological estradiol levels. In recent years, estradiol (E2) has been increasingly studied as a modulator of pain involved at the level of the dorsal horn and NMDA transmission. [6] [7] [8] However, the impact on pain modulation and pain perception of the supraphysiological levels of estradiol and the overall altered endocrine state seen in ART, have not been investigated.
Quantitative sensory tests (QSTs) evaluate the psychophysical response to experimental noxious stimuli, allowing quantification of clinically relevant pain thresholds and tolerance. [9] [10] [11] Simple bedside testing of mechanical temporal summation (mTS) with a Von Frey filament has been shown to predict acute postoperative pain 12, 13 and chronic pain disorders [14] [15] [16] in clinical studies. Only a handful of studies have utilized QST to evaluate the influence of hormonal stimulation for ART on pain perception, [17] [18] [19] and none has evaluated preprocedural pain testing or hormonal assays with postprocedural pain. Increased sensitivity to thermal cutaneous pain was found in 31 women undergoing ART but only at supraphysiological E2 levels. 17 No association between hormone levels at different time points during hormonal stimulation and a variety of QST was found in another study in 16 women undergoing ART, 18 and only reductions in cold water tolerance, but not in pressure pain, were found in another study in 40 women. 19 We decided to characterize post-egg retrieval pain and analgesic consumption, as well as identify clinical predictors for severe postprocedural pain, defined as a pain score of >7 on a numerical rating scale (NRS) from 0 to 10. We therefore designed a prospective, observational study exploring mTS, pain scores and analgesic intake, questionnaires to assess anxiety, fear and catastrophization traits (Spielberger State-Trait Anxiety Inventory, 20 Pain  Catastrophizing Scale, 21 Fear of Pain, 22 Short-form McGill  Pain Questionnaire) , 23 and hormonal levels to study the association between these parameters and post-egg retrieval pain.
MATERIALS AND METHODS

Ethical Consent
The study was approved by the University of Washington ethics committee (No. 35811-A), registered in the Clinical Trials Protocol Registration System (NCT00867945), and performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
Participants
Nulliparous women scheduled for egg retrieval after hormonal stimulation were approached the day before the egg retrieval procedure. Women were considered eligible if they were healthy, aged 18 to 45 years, ASA (American Society for ANesthesiologists) classification I-II 24 with no prior history of anxiety, no depression or chronic pain, and no chronic opioid consumption. Intake of nonsteroidal antiinflammatory drugs (NSAIDs) or acetaminophen 48 hours before egg retrieval was not allowed, as per clinical protocol at the Division of ART at the University of Washington.
Hormonal Assays
Before enrollment in the in vitro fertilization (IVF) cycle, antimullerian hormone (AMH), thyroid panel, prolactin, and baseline (day 2 to 4 of menstrual cycle) E2 and follicle-stimulating hormone levels were measured in all women. E2 levels were drawn at the start of the IVF cycle, on monitored stimulation days, and on the morning after human chorionic gonadotropin (hCG) administration (peak E2) ( Fig. 1 ).
Ultrasound Assessments
Serial transvaginal ultrasounds were performed per clinical protocol to determine follicular growth and timing for hCG administration, as well as the total follicle number (follicles >8 mm) and lead follicles (>14 mm). Follicle growth was assessed by serial transvaginal ultrasounds, starting from stimulation day 5 and thereafter as often as necessary to ensure that the antagonist and the hCG administration met protocol. On the day of hCG administration ultrasound assessment included recording total number and mean diameters for all follicles >8 mm size. Transvaginal ultrasound oocyte retrieval was performed 36 hours after hCG administration.
Ovarian Stimulation
IVF ovulation induction protocol ( Fig. 1 ) was initiated with oral contraceptive pretreatment. After a baseline transvaginal ultrasound, and evaluation of E2 and progesterone levels to confirm ovarian suppression (day 1 of a 10 d stimulation cycle), ovarian stimulation was initiated. A gonadotropin/antagonist/ovulation induction protocol was followed, which used a combination of recombinant FSH (Gonal-F, Merck Serono) and menotropin (Menopur, Ferring). With follicular recruitment achieving lead follicles of 12 to 13 mm mean diameter, a GnRH antagonist (Cetrotide, Merck Serono) was begun at a daily dose of 0.25 mg. With a lead follicle cohort of at least 17 mm mean diameter and a total serum E2 reflective of 200 to 250 pg/ mL per follicle, final oocyte maturation was induced by administering 10,000 IU of hCG (Noverel, Ferring).
Egg Retrieval Procedure
Using a standardized technique under ultrasound guidance and with general anesthesia, the aspiration needle (OVA-Stiff, 16 GA/35 cm; Cook Medical, Brisbane, QLD, Australia) was inserted through the vaginal wall and into the ovary. In a serial manner, follicular aspiration was performed of all follicles >13 mm size. To minimize the number of transvaginal/ovarian wall punctures, the needle was kept in the aspirated/collapsed follicle and advanced to the next adjacent follicle. Once all follicles in a given ovary were aspirated and oocyte identification completed, the needle was removed. The pelvis and ovary were observed with transvaginal Doppler, and if necessary hemostasis was achieved with approximated manual abdominal pressure with vaginal probe pressure. With adequate observation of hemostasis, transvaginal egg retrieval was resumed and follicular aspiration of the remaining ovary was completed. Upon completion of the transvaginal egg retrieval and a transvaginal Doppler ultrasound confirming hemostasis, anesthesia was discontinued and patients transferred to the postanesthesia care unit (PACU). The luteal phase was supplemented daily with vaginal progesterone (Crinone 8%, Watson) and oral E2 6 mg (2 mg three times a day), beginning the morning after oocyte recovery.
Anesthesia and Post-egg retrieval Analgesia
Anesthesia was provided by a dedicated team of obstetric anesthesiologists following a standardized protocol and in keeping with clinical standards requested by the Division of ART at the University of Washington. This protocol included intravenous (IV) midazolam 2 mg, fentanyl 50 to 200 mg, propofol (1 to 2 mg/kg) titrated to loss of consciousness and maintained with a continuous infusion (50 to 150 mg/kg/min), ondansetron 4 mg, and dexamethasone 4 mg. At the end of the procedure and after regaining consciousness, women were monitored in the PACU for 2 hours, and offered oral hydrocodone 5 mg and acetaminophen 500 mg. Breakthrough pain was treated with additional IV fentanyl at the discretion of the anesthesiologist. Women were instructed to manage post-egg retrieval pain with hydrocodone 5 mg and acetaminophen 500 mg tablets per need.
Study Procedures
Written consent was obtained the morning of the procedure. Two research coordinators not involved with clinical care collected all the preprocedural questionnaires, and performed mTS and the 24 hours phone pain followup. The full study flow is presented in Figure 2 .
Questionnaires
On the day of egg retrieval and before any procedurerelated intervention was started, women completed written questionnaires recording demographic data, general health information, as well as validated questionnaires to assess anxiety, fear, and catastrophization traits (Spielberger State-Trait Anxiety Inventory, Pain Catastrophizing Scale, Fear of Pain, Short-form McGill Pain Questionnaire). 23, 25, 26 mTS In sum, mTS was evoked with a 180 g (#6.45) von Frey filament (North Coast Medical, San Jose, CA) applied to the volar aspect of the dominant forearm. Women were asked to report their pain intensity on a 101-point NRS (0 = no pain, 100 = worst pain imaginable) from a single stimulus pinprick. Subsequently, 10 repetitive stimuli with an interstimulus interval of 1 second were applied within an area of 1 cm in diameter using the same filament, and women were asked to rate the pain intensity of the last stimulus. The mTS score was calculated as the difference between the last and first pain scores, with a positive score indicating increased excitatory central pain facilitation, 12 as previously described. 13 Excluded ( . Study protocol. The entire IVF ovulation induction protocol is represented, with 10 to 21 days of pretreatment cycle, 10 days of stimulation cycle, 2 days of maturation cycle, the procedure, and 24 hours after the procedure. The study protocol included analysis of baseline E2, FSH, AMH levels, peak E2 levels, questionnaires, mTS, procedure-related parameters, as well as pain scores during the first 24 hours (all study measures are represented in bold red). AMH indicates antimullerian hormone; E2, estradiol; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; IVF, in vitro fertilization; mTS, mechanical temporal summation. Data presented as mean ± SD. AMH indicates antimullerian hormone; BMI, body mass index; E2, plasmatic estradiol between days 2 and 5; FSH, follicle-stimulating hormone between days 2 and 5; hydrocodone, analgesic intake of oral hydrocodone in the first 24 hours; mTS, mechanical temporal summation; NRS, numerical response scale; paracetamol, analgesic intake of oral paracetamol in the first 24 hours; peak E2, maximal plasmatic level measured after hormonal stimulation; peak pain, peak postprocedural pain (NRS scale from 0 to 10).
Pain Outcomes
Women were contacted by phone the day after the procedure and answered questions on a scripted interview assessing their peak pain (NRS 0 to 10; 0 = no pain, 10 = worst pain imaginable), analgesic consumption (tablets taken), and pain after taking pain medication (NRS 0 to 10; 0 = no pain, 10 = worst pain imaginable).
Statistical Analysis
Descriptive categorical and numerical variables are presented as percentages or means ± SD. P values <0.05 were considered significant. All available variables fulfilled normal distribution criteria. Mann-Whitney U tests were performed, investigating the impact of ovarian hyperstimulation syndrome (OHSS) on peak E2, basal AMH levels, and peak postprocedural pain. Data were analyzed using SPSS 19 (SPSS Inc., Chicago, IL).
RESULTS
During the study period, 20 women were enrolled into the study, with 18 completing all the measures and followup, as described in the study flowchart (Fig. 1) . The overview of all demographic parameters are presented in Table 1 ; pain measures and the Pearson product-moment correlation coefficients are presented in Table 2 .
Women received on average IV fentanyl of 97.2 ± 29.5 mg during the procedure and immediately after in the PACU. For postprocedural analgesia, women took on average 16.1 ± 13.2 mg oral hydrocodone and 1609 ± 1325 mg oral acetaminophen in the first 24 hours.
All women experienced moderate to severe postprocedural pain (NRS peak pain score Z3/10). The average peak pain score in the first 24 hours after the procedure was 5.0 ± 1.6. The average pain score after taking pain medication was 2.7 ± 1.6, which was significantly lower than the peak postprocedural pain score (P < 0.001) ( Fig. 3 ). Pain was described as sharp (n = 6), crampy (n = 14), and burning (n = 1). A majority of patients experienced more pain than they expected (n = 11).
A Pearson product-moment correlation coefficient was computed to assess the strength of the linear association between peak postprocedural pain, demographic data, mTS, and hormonal and procedural factors (number of retrieved eggs, surgical time, total follicles and lead follicles). Two separate standard multiple regressions were AMH indicates antimullerian hormone (ng/mL); BMI, body mass index; E2, peak plasmatic estradiol between days 2 and 5 (pg/mL); FSH, peak folliclestimulating hormone between days 2 and 5 (mIU/mL); hydrocodone, analgesic intake of hydrocodone in the first 24 hours (mg); mTS, mechanical temporal summation score (0 to 100); paracetamol, analgesic intake of paracetamol in the first 24 hours (mg); peak E2, maximal plasmatic level measured after hormonal stimulation (pg/mL); peak pain, peak postprocedural pain on a numerical response scale (0 to 10). performed to keep a minimal number of variables in this small data set and to avoid multicollinearity. 27, 28 A standard multiple regression analysis was conducted to assess potential correlations between age, body mass index, and mTS and peak postprocedural pain. The regression equation for predicting maximal postprocedural pain was: Peak post À procedural pain ¼ ð0:055ÂmTSÞ þ 0:031ÂBMI ð Þ À 0:116Âage ð Þ þ 8:502 
Retrieved Eggs Total Follicles
Lead Follicles AMH E2 @ day 3 FSH @ day 3 mTS Hydrocodone Procedure-related factors possibly explaining the maximal pain were evaluated separately for the abovestated reasons. A standard multiple regression analysis was conducted exploring the correlation of peak postprocedural pain with the number of retrieved eggs, surgical time, total follicles, and lead follicles. The regression equation for predicting peak postprocedural pain was:
Peak postprocedural pain ¼ 0:179Âretrieved eggs ð Þ þ 0:086Â ð total folliclesÞ À 0:270Âlead follicles ð Þ þ 0:002Âsurgical time ð Þ þ3:711 Peak postprocedural pain was significantly associated with 4 factors: basal AMH level (r = 0.549, P = 0.018), peak E2 level (r = 0.582, P = 0.011), the total number of follicles (r = 0.591, P = 0.010), and the number of retrieved eggs (r = 0.510, P = 0.031) (Fig. 4) . The linear combination of procedural factors (surgical time, number of retrieved eggs, total follicles, and lead follicles) was not significantly associated with postprocedural analgesic response, defined as the difference in pain score (NRS) between the peak postprocedural pain score and average pain score (NRS) after taking pain medication (F = 0.418, P = 0.793, R = 0.338).
Preprocedural mTS score was 2.47 ± 4.7 (on an NRS from 0 to 100; 0 = no pain and 100 = worst pain imaginable) and was neither associated with peak E2 levels (r = 0.090, P = 0.724), nor peak postprocedural pain (r = 0.266, P = 0.286). Peak E2 level was significantly associated with basal AMH level (r = 0.718, P = 0.001), the total number of follicles (r = 0.719, P = 0.001), the number of lead follicles (r = 0.638, P = 0.014), and the number of retrieved eggs (r = 0.831, P < 0.001).
The number of retrieved eggs was correlated with basal AMH level (r = 0.701, P = 0.001), the total number of follicles (r = 0.752, P < 0.001), and lead follicles (r = 0.752, P < 0.001). The total number of follicles was significantly correlated with basal AMH level (r = 0.591, P = 0.010) and lead follicles (r = 0.688, P = 0.002).
The linear combination of demographic factors (age, body mass index) and mTS was not significantly correlated with peak postprocedural pain (F 4,13 = 1.329, R = 0.471, R 2 = 0.222). The multiple correlation coefficient was 0.471, FIGURE 4 . Correlations between peak E2, baseline AMH, total number of follicles, and number of retrieved eggs with peak postprocedural pain. Correlations performed using Pearson correlation coefficient. A, Peak estradiol level correlated with peak pain after egg retrieval (representing the worst pain during the first 24 h after the procedure). B, Baseline AMH level correlated with peak pain after egg retrieval (representing the worst pain during the first 24 h after the procedure). C, Number of total follicles correlated with peak pain after egg retrieval (representing the worst pain during the first 24 h after the procedure). D, Number of retrieved eggs correlated with peak pain after egg retrieval (representing the worst pain during the first 24 h after the procedure). AMH indicates antimullerian hormone.
indicating that approximately 22% of the variance of peak postprocedural pain can be accounted for by the linear combination of the predictors.
The linear combination of procedural factors (surgical time, number of retrieved eggs, total follicles, and lead follicles) was significantly correlated with peak postprocedural pain (F 4,13 = 4.756, P = 0.014). The multiple correlation coefficient was 0.771, indicating that approximately 60% of the variance of peak postprocedural pain can be accounted for by the linear combination of predictors, with the number of eggs (P = 0.032) and the number of lead follicles (P = 0.009) being statistically significant.
There were 4 cases diagnosed with OHSS, using a cutoff of AMH level >3.5 ng/mL. 29 Mann-Whitney U tests were performed, to evaluate the impact of OHSS on peak E2, basal AMH levels, and peak postprocedural pain. Women with OHSS had significantly higher levels of AMH (6.42 ± 2.3 ng/ mL) than women without OHSS (1.72 ± 1.1 ng/mL; z = À2.91; P = 0.004; mean rank with OHSS = 14.5, without OHSS = 6.5). Peak postprocedural pain scores were higher in women with OHSS (z = À 1.96; P = 0.049; mean rank with OHSS = 12.5, without OHSS = 7.17). Peak E2 did not correlate with OHSS (z = À1.57, P = 0.13; mean rank with OHSS = 11.75, without OHSS = 7.42).
DISCUSSION
The main findings in this study are that women undergoing ultrasound-guided egg retrievals report moderate to severe peak procedural pain that is described by most as sharp and exceeding their expectations. In addition, basal AMH levels and peak E2 levels were found to correlate with peak postprocedural pain, and may be used as predictors for severe pain in women with high preprocedural hormonal levels. Basal AMH levels have been associated with the total number of follicles on the day of the procedure, peak E2 levels, and number of retrieved eggs, 30 and are used as a predictor for follicular recruitment and influence medication protocols for adjusting gonadotropin stimulation, 31,32 but we provide here novel information suggesting it is also associated with the intensity of postprocedural pain. This association of basal AMH level and peak post-egg retrieval pain was not expected. Basal AMH levels >3.5 ng/mL have been associated with ovarian hyperstimulation 29 ; and in our cohort, 4 women met criteria for OHSS.
If ovarian distention is the main contributor to postprocedural pain, it would be expected that both the total number of recruited follicles as well as the number of lead follicles are associated with postprocedural pain. In our study, only the total number of recruited follicles and the number of retrieved eggs, but not the number of lead follicles, correlated in a multiple regression analysis predicting peak postprocedural pain. Our data suggest that the altered endocrine state seen in women undergoing fertility treatment contributes to postsonographic egg recovery pain modulation; in particular, the hormonal contribution related to the supraphysiological levels of estradiol seen in ART in contrast to mechanical, anatomic, or procedurerelated factors are causation for the postprocedural pain. The exact implications of this finding remains to be established, and may be limited to our small sample.
The intensity of pain reported by our cohort of women is substantially higher than that reported in a recent systematic review. 5 Explanations for this finding may be related to several factors, including the fact that women in our study did not receive regional anesthesia or local anesthetics, were not allowed to take NSAIDs before or after the procedure, and were given acetaminophen and hydrocodone-based tablets, which may not be as effective for crampy pain as other analgesic/anesthetic modalities. In addition, with 4 cases of OHSS (22% of our cohort), higher pain scores can be anticipated as we and others 19 found that supraphysiological levels of E2 are associated with higher sensitivity to pain.
In a recent study evaluating symptoms such as abdominal pain and cramping, bloating, headaches, nausea, increased thirst, sweating, hunger, anxiety, irritability, vaginal discomfort, and fatigue in 51 women undergoing IVF and 12 healthy controls, peak E2 levels were temporally associated with peak physical symptoms in the IVF group, supporting the hypothesis that increasing E2 levels influence symptom severity. 3 We evaluated mTS preoperatively, as this simple test has been previously shown to be associated with acute postoperative pain, 12 and we hypothesized that in the context of high estrogen impregnation, increased ascending noxious input may result in abnormal wind-up of pain. We did not find any correlation between mTS values and any of the outcomes. The lack of association with any of the measures' outcomes and specifically with peak procedural pain is most likely due to the fact that women in our cohort were all healthy, with no history of chronic pain, and were found to all have extremely low scores of mTS, therefore this test could not serve as a predictor in this setting. Alternatively, mTS may not be the most specific QST to predict pain that is essentially crampy by nature. On the basis of our findings, we can only conclude that mTS scores in otherwise healthy women do not seem to increase with the endocrine state induced by IVF.
We are aware of several limitations in our study design, which require cautious interpretation of our findings. First, we acknowledge our small sample size, which was in part due to our desire to ensure the most standardized hormonal stimulation protocol and procedure technique, so we only enrolled cases performed by 1 specific ART provider. Second, women did not receive NSAIDs (as per protocol established by the ART provider), which resulted in relatively high pain scores in all women. Last, we did not examine the effect of elevated AMH levels and peak E2 on pain perception after different procedures or in a context that is not related with egg retrievals, therefore more studies will be needed to establish the correlation and potential mechanisms by which these 2 hormones may be negatively influencing pain perception in women.
In sum, to the best of our knowledge, this is the first study evaluating preprocedural hormonal levels, mTS, and procedural factors in the context of post-egg retrieval pain and analgesic consumption. Although the sample size is small and results have to be interpreted with caution, our findings are consistent and provide robust evidence for a correlation between basal AMH levels, peak E2 levels, and the intensity of post-egg retrieval pain. These findings linking hormonal levels to pain merit further investigation to improve postprocedural management.
